Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJeffrey A. Cohen, Ludwig Kappos, Hans-Peter Hartung et al.|Journal of Neurology Neurosurgery & Psychiatry|2015Cited by 163
Switching from natalizumab to fingolimodLudwig Kappos, Athanasios P. Kyritsis, Ernst‐Wilhelm Radue et al.|Neurology|2015Cited by 116